Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Assets (2016 - 2025)

Historic Current Assets for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $643.2 million.

  • Ultragenyx Pharmaceutical's Current Assets fell 1955.98% to $643.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $643.2 million, marking a year-over-year decrease of 1955.98%. This contributed to the annual value of $817.1 million for FY2024, which is 1160.08% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Current Assets stood at $643.2 million for Q3 2025, which was down 1955.98% from $719.8 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Current Assets peaked at $1.1 billion during Q1 2021, and registered a low of $596.0 million during Q1 2024.
  • Its 5-year average for Current Assets is $791.9 million, with a median of $766.3 million in 2023.
  • In the last 5 years, Ultragenyx Pharmaceutical's Current Assets plummeted by 4083.08% in 2023 and then soared by 3738.63% in 2024.
  • Ultragenyx Pharmaceutical's Current Assets (Quarter) stood at $856.6 million in 2021, then increased by 3.19% to $883.9 million in 2022, then fell by 17.16% to $732.2 million in 2023, then rose by 11.6% to $817.1 million in 2024, then dropped by 21.28% to $643.2 million in 2025.
  • Its last three reported values are $643.2 million in Q3 2025, $719.8 million for Q2 2025, and $699.2 million during Q1 2025.